What do we get for our money? Cost-effectiveness of adding contingency management

Addiction

Volumn 102, Issue 2, 2007, Pages 309-316

  Sindelar, Jody ^a,b   Elbel, Brian ^a   Petry, Nancy M ^c  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NATIONAL BUREAU OF ECONOMIC RESEARCH   (United States)

^c UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

Author keywords

Cocaine abuse; Contingency management; Cost effectiveness; Substance abuse treatment

Indexed keywords

COCAINE;

ABSTINENCE; ARTICLE; COCAINE DEPENDENCE; COMMUNITY BASED REHABILITATION; CONTROLLED STUDY; COST; COST EFFECTIVENESS ANALYSIS; DRUG WITHDRAWAL; EVIDENCE BASED MEDICINE; GOAL ATTAINMENT; HEALTH CARE COST; HEALTH CARE MANAGEMENT; HEALTH CARE POLICY; HEALTH CARE UTILIZATION; HEALTH CENTER; HEALTH SURVEY; HUMAN; MAJOR CLINICAL STUDY; MONEY; OUTCOME ASSESSMENT; OUTPATIENT; PARTICIPATORY MANAGEMENT; PATIENT COUNSELING; SENSITIVITY ANALYSIS; URINALYSIS;

ADOLESCENT; ADULT; AGED; COCAINE-RELATED DISORDERS; COST-BENEFIT ANALYSIS; FEMALE; HUMANS; MALE; METHADONE; MIDDLE AGED; MOTIVATION; NARCOTICS;

EID: 33846191488     PISSN: 09652140     EISSN: 13600443     Source Type: Journal    
DOI: 10.1111/j.1360-0443.2006.01689.x     Document Type: Article

References (33)

1. Higgins S. T., Budney A. J., Bickel W. K., Foerg F., Donham R., Badger G. J. Incentives improve outcome in out-patient behavioral treatment of cocaine dependence. Arch Gen Psychiatry 1994; 51: 568-76.
2. Silverman K., Higgins S. T., Brooner R. K., Montoya I. D. Sustained cocaine abstinence in methadone maintenance patients through voucher-based reinforcement therapy. Arch Gen Psychiatry 1996; 53: 409-15.
3. Budney A. J., Higgins S. T., Radonovich K. J., Novy P. L. Adding voucher-based incentives to coping skills and motivational enhancement improves outcomes during treatment for marijuana dependence. J Consult Clinl Psychol 2000; 68: 1051-61.
4. Higgins S. T., Wong C. J., Badger G. J., Ogden D., Dantona R. I. Contingent reinforcement increases cocaine abstinence during out-patient treatment and one year of follow-up. J Consult Clin Psychol 2000; 68: 64-72.
5. Petry N. M., Tedford J., Austin M., Nich C., Carroll K., Rounsaville B. Prize reinforcement contingency management for treating cocaine user: how low can we go, and with whom? Addiction 2004; 99: 349-60.
6. Petry N. M., Martin B., Cooney J. L., Kranzle H. R. Give them prizes and they will come. Contingency management for the treatment of alcohol dependence. J Consult Clin Psychol 2000; 68: 250-7.
7. Petry N. M., Martin B., Finocche C. Contingency management in group treatment: a demonstration project in an HIV drop-in center. J Subst Abuse Treat 2001; 21: 89-96.
8. Petry N. M., Martin B. Lower-cost contingency management for treating cocaine-abusing methadone patients. J Consult Clin Psychol 2002; 70: 398-405.
9. Barnett P. G., Zaric G. S., Brandeau M. L. The cost-effectiveness of buprenorphine maintenance therapy for opiate addiction in the United States. Addiction 2001; 96: 1267-78.
10. French M. T., Mausopf J. A., Teague J. L., Roland J. Estimating the dollar value of health outcomes from drug abuse interventions. Med Care 1996; 34: 890-910.
11. French M. T., Salome H. I. J., Sindelar J. L., McLellan A. T. Benefit cost analysis of addiction treatment. Methodological guidelines and applications using the DATCAP and ASI. Health Serv Res 2002; 37: 433-55.
12. French M. T., McGeary K. A. Estimating the economic cost of substance abuse treatment. Health Econ 1997; 6: 539-44.
13. Sindelar J. L., Manning W. G. Cost-benefit and cost-benefit analysis: issues in the evaluation of the treatment of illicit drug abuse. In: Egertson J., Fox D., Leshner A., editors. Treating drug abusers effectively. Malden, MA, USA: Blackwell 1997, p. 187-222.
14. Sindelar J. L., Jofre-Bonet M., French M. T., McLellan T. A. Cost-effectiveness analysis of treatments for illicit drug dependence: paradoxes with multivariate outcomes. J Drug Alcohol Depend 2004; 73: 41-50.
15. Jofre-Bonet M., Sindelar J. L., Petrakis I., Nich C., Frankforter T., Rounsaville B. J. et al. Cost-effectiveness of disulfiram: treating cocaine use in methadone-maintained patients. J Subst Abuse Treat 2004; 26: 225-32.
16. Avants S. K., Margolin A., Sindelar J. L., Rounsanville B. J., Schottenfield R., Stine S. et al. Day treatment versus enhanced standard methadone services for opioid-dependent patients: a comparison of clinical efficiency and cost. Am J Psychiatry 1999; 156: 27-33.
17. Hartz D. T., Meek P., Piotrowski N. A., Tusel D. J., Henke C. J., Delucchi K. et al. A cost-effectiveness and cost-benefit analysis of contingency contracting-enhanced methadone detoxification treatment. Am J Drug Alcohol Abuse 1999; 25: 207-18.
18. Schumacher J. E., Mennemeyer S. T., Milby J. B.,Wallace D., Nolan K. Costs and effectiveness of substance abuse treatments for homeless persons. J Ment Health Policy Econ 2002; 5: 33-42.
19. Cartwright W. S. Cost benefit and cost-effectiveness analysis of drug abuse treatment services. Eval Rev 1998; 22: 609-36.
20. Cartwright W. S. Cost-benefit analysis of drug treatment services: review of the literature. J Ment Health Policy Econ 2000; 3: 11-26.
21. Drummond M. F., O'Brien B., Stoddart G. L., Torrance G. W. Methods for the Economic Evaluation of Health Care Programs, 2nd edn. New York/Oxford: Oxford University Press; 1997.
22. Gold M. R., Siegel J. E., Russell L. B.,Weinstein M. C., editors. Cost-Effectiveness in Health and Medicine. New York/Oxford: Oxford University Press; 1996.
23. Carroll K. M., Nich C., McLellan A. T., McKay J. R., Rounsaville B. J. 'Research' versus 'real-world' patients: representativeness of participants in clinical trials of treatments for cocaine dependence. Drug Alcohol Depend 1999; 54: 171-7.
24. McLellan A. T., Alterman A. I., Metzger D. S., Grisson G. R., Woody G. E., Luborsky L. et al. Similarity of outcome predictors across opiate, cocaine, and alcohol treatments: role of treatment services. J Consult Clin Psychol 1994; 62: 1141-58.
25. Petry N. M., Tedford J., Martin B. Reinforcing compliance with non-drug related activities. J Subst Abuse Treat 2001; 20: 33-44.
26. Petry N. M., Pierce J., Stitzer M. L., Blaine J., Roll J. M., Cohen A. et al. Prize-based incentives improve outcomes of stimulant abusers in out-patient psychosocial treatment programs: a national drug abuse treatment clinical trials network study. Arch Gen Psychiatry 2005; 62: 1148-56.
27. Zarkin G. A., Dunlap L. J., Homsi G. The Substance Abuse Services Cost Analysis Program (SASCAP): a new method for estimating drug treatment services costs. Eval Program Plann 2004; 27: 35-43.
28. Lothgren M., Aethraeus N. Definition, interpretation and calculation of cost-effectiveness acceptability curves. Health Econ 2000; 9: 623-30.
29. Fenwick E., Claxton K., Schulpher M. Representing uncertainty. The role of cost-effectiveness acceptability curves. Health Econ 2001; 10: 779-87.
30. Fenwick E., O'Brien B. J., Briggs A. Cost-effectiveness acceptability curves - facts, fallacies and frequently asked questions. Health Econ 2004; 13: 405-15.
31. Polsky D., Glick H. A., Willke R. , Schulman K. Confidence intervals for cost-effectiveness ratios: a comparison of four methods. Health Econ 1997; 6: 243-52.
32. Van Hout B. A., Al M. J., Gordon G. S., Rutten F. F. H. Costs, effects and c/e ratios alongside a clinical trial. Health Econ 1994; 3: 309-19.
33. Petry N. M. A comprehensive guide for the application of contingencymanagement procedures in standard clinic settings. Drug Alcohol Depend 2000; 58: 9-25.